Millipore begins global shipments of Scepter Handheld Automated Cell Counter

NewsGuard 100/100 Score

Millipore Corporation (NYSE: MIL), a leading provider of technologies, tools and services for the global life science industry, today announced it has begun full commercial shipments of its Scepter™ Handheld Automated Cell Counter to customers worldwide.

“We continue to move aggressively to bring innovation and productivity enhancements to the life science research market”

The Scepter instrument miniaturizes Coulter cell counting technology found in much larger instruments into a portable device the size of an automated pipette. A graphical display reports the cell count and average cell volume within 20 seconds of inserting the sensor into a cell culture sample. The product, which was announced in the fourth quarter of 2009, has generated strong interest from leading government and commercial laboratories. Millipore expects to continue to increase shipments in North America, Europe, Japan, Asia and Latin America through the remainder of the year.

"We continue to move aggressively to bring innovation and productivity enhancements to the life science research market," said John Sweeney, Vice President of Millipore's Life Science business. "With the introduction of the Scepter instrument, we now have a range of tools that help life scientists simplify tedious, repetitive tasks and improve the reproducibility of their experiments."

In addition to counting cells, the Scepter instrument gives researchers immediate insights into cell health. For example, scientists are using the instrument to monitor the transformation of stem cells to a differentiated state. The novel instrument is also being evaluated for such diverse applications as identifying cell types prior to forensic analysis and analyzing the size and consistency of particles during the commercial production of ink.

SOURCE Millipore Corporation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Asimov achieves 10x improvement in lentiviral production, launches new stable cell line development service